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Case Report

A 30 year old male with a remote history of intravenous drug
abuse (IVDA) and Hepatitis C was admitted in July 2008
with changes in mental status and a new right sided paresis.
According to the family, the patient was in his usual state
of health until approximately 2-3 weeks prior to admission
when he developed headaches, generalized malaise, and fever
to 101 degrees Fahrenheit after swimming in a lake. He was
seen in an outside hospital emergency department, diagnosed
with otitis media and subsequently discharged on prednisone
and ciprofloxacin. The morning of admission, the patient was
found naked, nonverbal, confused and was subsequently taken
again to an outside hospital emergency department where he
was found to have right sided weakness, diagnosed with a new
cerebrovascular accident (CVA) and transferred to TJUH for
further management.

of embolic source of the patient’s CVA. The patient had a
transthoracic echocardiogram which showed a myxomatous
appearing mitral valve with an echodensity near the base
of the posterior mitral valve with vegetations (Figure 3). A
transesophageal echocardiogram revealed a mobile 0.5 cm x 0.5
cm echodensity attached to the posterior mitral valve leaflet as
well as a second 0.9 cm x 0.5 cm echodensity attached to the
anterior mitral valve leaflet (Figure 4). Of note, the patient’s
TEE bubble study revealed patent foramen ovale (PFO), which
is postulated to have contributed to the presence left sided
infectious endocarditis in a patient with IVDA.
Given the patient’s history of IVDA, he was started on vancomycin
for Staphylococcus aureus via a peripherally inserted central
catheter. A few days later, the organism was found to be sensitive
to methicillin and antibiotics were adjusted apropriately.

On admission, the patient was found to have persistent right
sided hemiparesis, a new loud systolic murmur best heard at
the left lower sternal border and petechiae on his calves. Initial
labs revealed a leukocytosis with left shift. His CT scan showed
an acute left MCA territory infarction (Figure 1). A follow up
MRI revealed additional punctuate foci of restricted diffusion
in the right parietal and left occipital lobe (Figure 2), suggestive
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Figure 1. CT scan showing Hypoattenuation in Left Frontal
and Temporal lobes compatible with Acute Left MCA Territory
Infarct.

Figure 2. MRI showing acute infarct involving left frontal and
parietal lobes in left MCA distribution with punctate foci of
diffusion restriction consistent with embolic phenomena.

Infectious endocarditis (IE) has been described in the medical
literature for over 100 years. Prior to antibiotics, the condition
was uniformly fatal, with a majority of cases diagnosed at
autopsy. It wasn’t until the development of echocardiography
that there was a significant reduction in the morbidity and
mortality and mortality of IE.
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younger patients has resulted in an increase in the median age
of IE patients over the past 40 years.3

Figure 3. TTE showing myxomatous appearance of mitral valve
with vegetation

Independent of age or risk factors, the most common offending
organisms remain the same, with Staphylococcus aureus and
Streptococcus spp. (including viridians, bovis, and enterococcus)
being the most common. They have been associated with both
native and diseased valve endocarditis. Gram negative bacteria
including Haemophilus species (Haemophilus parainfluenzae,
Haemophilus aphrophilus, and Haemophilus paraphrophilus),
Actinobacillus actinomycetemcomitans, Cardiobacterium
hominis, Eikenella corrodens, and Kingella species (HACEK
organisms) have also been described as causes of infectious
endocarditis, particularly in non-IVDA patients. These
organisms have an increased affinity for adherence to native valve
tissue. However, they are much less common in comparison to S.
aureus and Streptococcus spp and are responsible for only 5-10%
of non-IVDU native valve IE cases.4
Those patients that develop IE, with or without prophylaxis,
may present with a wide variety of clinical features. Some may
present with classic signs and symptoms of low grade fevers,
a new murmur, petechiae, Roth spots, Janeway lesions, and
Osler’s nodes. The last three findings are highly specific and
pathognomonic for IE, but have a low rate of occurrence.
Often, some of the features may not be visible at the time of
presentation. Occasionally, some patients, including the one
presented, will present with symptoms of embolic phenomena.
The diagnosis of IE primarily includes clinical and echocardiographic criteria, divided into major and minor criteria (Table
1). Recently, the Duke Criteria were modified to include the
echocardiographic criteria, as well as to distinguish between
definite, probable, and rejected categories (Table 2).

Figure 4. TEE showing large vegetation on mitral valve.
Presently, there are 10-15,000 new cases of IE diagnosed in the
United States each year1 with estimated national incidences
ranging from 1.4 to 6.2 per 100,000.2 Moreover, epidemiology
reports from the early 1990’s, report incidences as high as 11 per
100,000 in the Philadelphia area.1 In particular, IE has become
more a disease of the elderly as over half of all new cases occur
in those over the age of 60.3
This older demographic, in addition to previously noted
conditions of intravenous drug abuse, structural heart disease,
and recurrent bacteremia may have additional risk factors
that predispose them to develop IE. These include patients
on hemodialysis, with indwelling catheters, severe native and/
or artificial valve disease, diabetes, intravenous drug abuse,
and HIV infection. These additional factors, coupled with a
significant decline in rheumatic heart disease as a risk factor in
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Treatment of IE is directed towards the causative organism as
well as the degree of valvular dysfunction. Staphylococcal and
Streptococcal species are usually responsive to intravenous
vancomycin, pencillins or third generation cephalosporins. If
Table 1. Modified Duke major and minor criteria for
diagnosis of Infectious endocarditis [Li, JS, Sexton, DJ,
Mick, N, et al. Clin Infect Dis 2000; 30:633]
Major Criteria

Minor Criteria

1. Blood cultures positive for
typical organisms

1. Predisposing heart lesions

2. positive cultures 12 hours
apart

3. Fever

3. 3 of 3 positive from
different sites
4. Majority of > 3 cultures
positive
5. Echocardiogram positive
for IE

2. IVDA
4. Vascular lesions:
5. Janeway lesions, emboli,
septic infarcts, hemorrhages
6. Immunologic phenomena
Glomerulonephritis,
Osler’s nodes, Roth spots,
Rheumatoid Factor
7. Microbiologic evidence not
meeting major criteria

Table 2. Diagnosis of IE based on modified Duke Criteria
in Table 1 [Li, JS, Sexton, DJ, Mick, N, et al. Clin Infect
Dis 2000; 30:633]
Definite Diagnosis of IE
2 Major OR
1 Major and 3 Minor OR
5 Minor

Possible Diagnosis of IE
Major and 1 Minor OR
3 Minor

Rejected Diagnosis of IE
Firm alternate diagnosis other than IE
Resolution of symptoms with 4 days of Antibiotics
No pathologic evidence of IE
No echocardiographic evidence of IE

there is significant valvular dysfunction, cardiothoracic surgery
consultation is warranted for valve repair and/or replacement.5
Since there is a significant morbidity and mortality associated
with IE, focus has shifted towards prevention in those patients
at increased risk. However, as previously mentioned, the group
of patients “at risk” can encompass a wide array of individuals.
As a result of this broadening category of “at risk” patients, it
was necessary to identify those at high enough risk to warrant
prophylaxis with antibiotics. Recently, the American College of
Cardiology and the American Heart Association in conjunction

with the Infectious Disease Society of America have reviewed
the data on prevention of IE and have subsequently revised the
guidelines regarding antibiotic prophylaxis (Table 3). These
guidelines reflect significant changes from previously published
ones and are based on the evidence for, or lack thereof, the
efficacy of prophylaxis in patients identified as high risk for IE.6
Amoxicillin is the antibiotic of choice for the majority of
patients requiring prophylaxis and is given in a dose of 2 grams
orally approximately 30 to 60 minutes prior to the procedure.
Patients with a documented allergy to penicillins may be given
any of the following 30 to 60 minutes prior to the procedure: 2
grams of cephalexin, 500 milligrams of either azithromycin or
clarithromycin, or 600 milligrams of clindamycin.6
In conclusion, IE is a real but preventable entity once the high
risk patients have been identified. A review of recent data has
greatly narrowed the number of patients considered “high risk”
and has simultaneously limited the instances in which antibiotic
prophylaxis is necessary. However, narrowing the spectrum of
patients in which prophylaxis does not preclude the necessity
of a pre-emptive approach in preventing infectious endocarditis
and its sequelae.
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Table 3. Updated ACC/AHA/ID Society
recommendations for prophylaxis against IE6
1.

Although IE is a serious condition, the efficacy of antimicrobial prophylaxis is uncertain in all but a few select instances. Therefore,
there are no longer any Class I recommendations for IE prophylaxis in patients with valvular heart disease.

2.

Antibiotic prophylaxis during dental procedures would prevent only a small proportion of cases of IE, even if it were 100%
effective.

3.

IE prophylaxis during dental procedures is appropriate only in patients with underlying cardiac conditions associated with the
highest risk for adverse outcomes. These conditions include:
a.

prosthetic valves or material

b.

Prior IE

c.

Unrepaired cyanotic congenital heart disease (CHD) including shunts and conduits

d.

Complete CHD repair within previous 6 months

e.

Complete CHD repair with residual defects

f.

Valve regurgitation secondary to structural abnormalities in cardiac transplant recipients

4.

In such high-risk patients, prophylaxis is appropriate for all dental procedures involving manipulation of gingival tissue or the
periapical region of teeth, or perforation of oral mucosa (Class IIa).

5.

Increased lifetime risk for IE alone is not an indication for antibiotic prophylaxis

6.

Antibiotic IE prophylaxis is no longer indicated in patients with aortic stenosis, mitral stenosis, or symptomatic or asymptomatic
mitral valve prolapse.

7.

Antibiotic IE prophylaxis is no longer indicated in adolescents and young adults with native heart valve disease.

8.

Genitourinary and gastrointestinal tract procedures (transesophageal echocardiography, esophagogastroduodenoscopy,
colonoscopy, etc.) do not warrant IE prophylaxis unless active infection is present.
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